A Targeted Solution in Glioblastoma Treatment
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
Meet two researchers on opposite ends of the globe dedicated to transforming the future of brain tumor treatments.
**Sponsored Content**
See how a cutting-edge imaging solution by Medexus Pharma is revolutionizing treatment outcomes for GBM patients.
Dr. Duane Mitchell, MD, PhD, Univ. of Florida, shares four highlights in recent GBM research and what he’s hopeful for in the future.
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631